Biochemical Pharmacology volume 81, issue 1, P104-110 2011 DOI: 10.1016/j.bcp.2010.09.015 View full text
|
|
Share
Clayton Yates, Starlette Sharp, Jacqueline Jones, Daphne Topps, Mathew Coleman, Ritu Aneja, Jesse Jaynes, Timothy Turner

Abstract: AbstractProstate cancer is the second leading cause of cancer deaths among men. For patients with hormone-refractory disease, few treatments are available once the tumor has metastasized beyond the prostate. In the present study, two conjugated lytic peptide sequences (named JCHLHRH and JC21LHRH) were designed to target luteinizing hormone-releasing hormone receptors (LHRH-R). Our results indicate that human prostate cancer cell lines were sensitive to both LHRH-conjugated and non-conjugated lytic peptides, w…

expand abstract